Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 2,120 trials

Intra-Hepatic Cholangiocarcinoma: New Treatment Approaches

We are studying a combination of treatments for patients with inoperable intra-hepatic cholangiocarcinoma. The goal is to see if these treatments can improve survival and quality of life.

Non-resectable Cholangiocarcinoma>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboInvestigational MedicinesInternal MedicineOncology

Atopic Dermatitis: Methotrexate Injection Study

We are testing whether subcutaneous methotrexate can improve skin symptoms in adults with moderate to severe atopic dermatitis compared to a placebo. The study also examines safety and quality of life for participants.

Moderate to Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesAllergologyDermatology

HER2-Positive Solid Tumors: Disitamab Vedotin Study

We are studying a new treatment called disitamab vedotin for adults with advanced solid tumors that express HER2 and have been previously treated. The trial aims to evaluate its effectiveness and safety.

Ovarian CancerHead and Neck CancerEndometrial Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Metastatic Breast Cancer: Somatostatin Receptor PET Scan Study

We are studying how somatostatin receptors behave in metastatic breast cancer using DOTATOC-68Ga PET scans. This may help us understand the disease better and improve future imaging techniques.

Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

SENS-501 for Children with Hearing Loss from Otoferlin Mutations

We are studying a new injection treatment for children with severe to profound hearing loss due to Otoferlin gene mutations. The trial will assess both the safety and effectiveness of this treatment.

Bilateral Severe to Profound Hearing LossSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOtolaryngology

Head and Neck Cancer: Pembrolizumab with Radiotherapy

We are studying if adding radiotherapy to pembrolizumab helps patients with limited spread of head and neck cancer live longer and feel better. This trial focuses on those with a specific type of cancer and aims to compare treatment effects and safety.

Squamous Cell Carcinoma of the Head and Neck>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Aortic Stenosis: Protamine for Heart Procedure Safety

We are studying whether using protamine sulfate can reduce complications like strokes and bleeding during heart valve surgery. This trial is for patients with aortic stenosis undergoing transcatheter aortic valve implantation.

Cardiovascular Disorder>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Acquired Hemophagocytic Syndrome: Ruxolitinib Study

We are studying whether ruxolitinib, combined with standard care, can improve organ function and survival in critically ill patients with acquired hemophagocytic syndrome. This trial also looks at the safety and effects of the drug on various health markers.

Haemophagocytic Syndrome1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInternal Medicine

Large Incisional Hernia: Botulinum Toxin A Injection Study

We are investigating whether injecting botulinum toxin A before surgery helps reduce complications and improve recovery for patients with large incisional hernias. This study compares the effects of BTA to a placebo injection.

Incisional Hernia>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementGastroenterologyOrthopedics and Traumatology

GVHD Prevention in Elderly AML/MDS Patients: Thymoglobulin vs. Grafalon

We are comparing two treatments to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome receiving stem cell transplants. The goal is to find out which treatment leads to better outcomes after transplantation.

Acute Myeloid LeukemiaMyelodysplastic Syndrome>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Trigeminal Neuralgia: Botox Treatment Study

We are exploring whether Botox can effectively reduce pain in patients with trigeminal neuralgia compared to a placebo. Additionally, we’re investigating if specific biomarkers can help predict treatment response.

Trigeminal Neuralgia3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Carotid Stenosis: Ficolin-2 and Inflammation Study

We are investigating how levels of ficolin-2 relate to inflammation in the carotid arteries and brain in patients who have had a stroke or transient ischemic attack. This research may help us understand the underlying causes of these conditions better.

Stroke or Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNeurology

Hypotension Treatment: Early Vasopressor Therapy

We are studying whether starting vasopressor therapy early helps hypotensive patients in the emergency department recover faster than standard fluid therapy. This may reduce the need for intensive care admission.

Low Blood Pressure (Hypotension)Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious DiseasesInternal MedicinePulmonology

Advanced Non-Small Cell Lung Cancer: THIO with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining THIO and cemiplimab for people with advanced non-small cell lung cancer. This trial aims to find out if this combination works better than THIO alone for patients who have already been treated.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Hepatocellular Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a combination of two medications for people with advanced liver cancer who have not had prior treatment. The goal is to find the best dose and assess safety and effectiveness.

Metastatic Liver Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyOncology

Cell Therapy for Acute Kidney Injury After Heart Surgery

We are studying whether modified autologous leukocyte cells can help patients recover kidney function after developing acute kidney injury following cardiac surgery. The trial will also assess the safety of this new treatment.

Acute Kidney Injury6-12 monthsEfficacy phase (II)Investigational MedicinesCardiologyNephrology

Colorectal Liver Metastases: SGM-101 and Indocyanine Green Imaging

We are studying the use of two imaging agents during surgery for colorectal liver metastases to see if they help surgeons remove cancerous tissue more effectively. This trial aims to improve surgical accuracy and patient outcomes.

Liver Metastases1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Triple-Negative Breast Cancer: Pembrolizumab and Chemotherapy Study

We are investigating whether adding pembrolizumab to chemotherapy improves outcomes for patients with early-stage triple-negative breast cancer based on their tumor-infiltrating lymphocyte levels. This study also looks at the safety and quality of life for participants.

Triple Negative Breast Cancer6-12 monthsEfficacy phase (II)Standard MedicinesOncology

Severe Brain Injury: Apomorphine Treatment Study

We are investigating whether apomorphine can help patients with disorders of consciousness. The study also aims to identify which patients may respond best to this treatment.

Severe Brain Injury and Disorder of Consciousness≤3 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology